Tobi Podhaler Inhalation Powder, Capsule 28Mg Drug Medication Dosage Information
show timeout overlay link

Your Session Is About to Expire

This online session is about to expire due to inactivity. Click Continue to return to page.

  • myWeekly Ad

TOBI Podhaler: Inhalation powder, capsule (28mg)

Also see:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics

Visit Drug Summary Page
Drug Image file default-drug-image.png


What is this Medicine?

TOBRAMYCIN (toe bra MYE sin) is an aminoglycoside antibiotic. It is used to treat or prevent certain kinds of bacterial infections in the lungs. It will not work for colds, flu, or other viral infections.

In-Depth Information

TOBI Podhaler 28mg Powder for Inhalation

NDC: 000780630
  • Prescription Required
  • Not a Controlled Drug
    (CSA Schedule)
  • FDA Approved




FDA approved for the following conditions:
Cystic Fibrosis

Storage Information
Protect from moisture
Store at 77 degrees F; excursions permitted to 59-86 degrees F
TOBI Podhaler 28mg Powder for Inhalation

Reported Side Effects for TOBI Podhaler 28mg Powder for Inhalation

Stevens-Johnson Syndrome Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Anaphylactoid Reactions Incidence:
<1.0%*
Severity: SEVERE
Onset: RAPID
Lyell'S Syndrome Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Exfoliative Dermatitis Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Erythema Multiforme Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Breathing Difficulties Incidence:
0.5-5.0%*
Severity: SEVERE
Onset: RAPID
Metallic Taste Incidence:
0.5-6.6%*
Severity: MILD
Onset: EARLY
Nose Bleed Incidence:
1.9-7.0%*
Severity: MILD
Onset: DELAYED
Throat Irritation Incidence:
1.9-4.5%*
Severity: MILD
Onset: EARLY
Loose Stools Incidence:
1.9-6.2%*
Severity: MILD
Onset: EARLY
Eosinophilia Incidence:
2.0%*
Severity: MODERATE
Onset: DELAYED
Skin Rash Incidence:
2.3-5.4%*
Severity: MILD
Onset: EARLY
Ringing In Ears Incidence:
3.1%*
Severity: MILD
Onset: DELAYED
Hoarseness Incidence:
3.8-13.6%*
Severity: MODERATE
Onset: DELAYED
Inflamed Vocal Cords Incidence:
4.3%*
Severity: MILD
Onset: DELAYED
Chest Pain Incidence:
4.5-26.0%*
Severity: MODERATE
Onset: EARLY
Muscle Pain Incidence:
4.7%*
Severity: MILD
Onset: EARLY
Wheezing Incidence:
5.0-6.8%*
Severity: MODERATE
Onset: RAPID
Overbreathing Incidence:
5.4%*
Severity: MILD
Onset: EARLY
Vomiting Incidence:
5.7-14.0%*
Severity: MILD
Onset: EARLY
Feeling Sick Incidence:
6.2%*
Severity: MILD
Onset: EARLY
Back Pain Incidence:
7.0%*
Severity: MILD
Onset: DELAYED
Stuffy Nose Incidence:
7.2-8.1%*
Severity: MILD
Onset: EARLY
Upset Stomach Incidence:
7.5-11.2%*
Severity: MILD
Onset: EARLY
Sinus Infection Incidence:
8.1%*
Severity: MILD
Onset: DELAYED
Cough Incidence:
10.0-46.1%*
Severity: MILD
Onset: DELAYED
Weight Loss Incidence:
10.1%*
Severity: MILD
Onset: DELAYED
Headache Incidence:
11.4-26.7%*
Severity: MILD
Onset: EARLY
Coughing Up Blood Incidence:
12.4-19.4%*
Severity: MODERATE
Onset: DELAYED
Shortness Of Breath Incidence:
12.4-33.7%*
Severity: MODERATE
Onset: EARLY
Fever Incidence:
12.4-32.9%*
Severity: MILD
Onset: EARLY
Stomach Pain Incidence:
12.8%*
Severity: MILD
Onset: EARLY
Decreased Appetite Incidence:
18.6%*
Severity: MILD
Onset: DELAYED
Rhinitis Incidence:
34.5%*
Severity: MILD
Onset: EARLY
Weakness Incidence:
35.7%*
Severity: MILD
Onset: DELAYED
Sore Throat Incidence:
38.0%*
Severity: MILD
Onset: DELAYED
*This is an approximate aggregated range of reported side effects from clinical studies performed on this drug. Your experience with this drug may be different.
Pregnancy & Lactation Information
FIRST Trimester

Class D - Adequate well-controlled or observational studies in pregnant women have demonstrated a risk to the fetus. However, the benefits of therapy may outweigh the potential risk. For example, the drug may be acceptable if needed in a life-threatening situation or serious disease for which safer drugs cannot be used or are ineffective.

SECOND Trimester

Class D - Adequate well-controlled or observational studies in pregnant women have demonstrated a risk to the fetus. However, the benefits of therapy may outweigh the potential risk. For example, the drug may be acceptable if needed in a life-threatening situation or serious disease for which safer drugs cannot be used or are ineffective.

THIRD Trimester

Class D - Adequate well-controlled or observational studies in pregnant women have demonstrated a risk to the fetus. However, the benefits of therapy may outweigh the potential risk. For example, the drug may be acceptable if needed in a life-threatening situation or serious disease for which safer drugs cannot be used or are ineffective.

Lactation

Compatible - This drug is generally safe to take by nursing mothers.


Learning More About
Visit the Drug Summary page where you can:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics
Learn More
Patient Experiences with TOBI Podhaler

Be the first to share your experience!

We want to help our customers stay educated about the medications they are taking. Submit your own observations and experiences to benefit others.

Average Scores
Easy to Take 
0 / 5
0 / 5
Works as Intended 
0 / 5
0 / 5
Tolerable 
0 / 5
0 / 5